The persistent pursuit of a sun-kissed glow, despite decades of public health warnings, reveals a deeper tension: how do we balance individual autonomy with demonstrable health risks, particularly when those risks fall disproportionately on young people? This question is at the heart of the Food and Drug Administration’s (FDA) surprising decision this week to withdraw a proposed rule that would have nationally banned tanning bed use for anyone under 18. While headlines declared the rule “dead,” a closer look at the agency’s reasoning, the volume of opposing comments, and the existing patchwork of state laws reveals a far more nuanced – and concerning – situation than a simple policy reversal.
The proposed rule, initially put forward in 2015, wasn’t merely about banning access. It also mandated that all tanning salon patrons over 18 sign a waiver acknowledging the well-documented dangers of indoor UV radiation, including skin cancer and severe burns. Tanning beds aren’t simply a cosmetic concern; they can emit up to 15 times the amount of ultraviolet radiation compared to direct sunlight, significantly increasing the risk of DNA damage in skin cells. A 2025 study demonstrated that melanoma rates are more than double – approximately 5% versus 2% – among those who use tanning beds compared to those who don’t. The FDA’s withdrawal, signed by Health Secretary Robert F. Kennedy Jr., follows the receipt of over 8,100 comments, a figure that underscores the intensity of the debate.
However, the sheer number of comments doesn’t automatically validate the decision. The FDA’s notice explicitly states that commenters raised concerns about “personal choice and parental decision-making,” alongside anxieties about “compliance burdens on small businesses.” This framing suggests a prioritization of economic considerations and individual liberty over established public health guidance. It’s a familiar pattern – the tension between perceived freedom and demonstrable harm – and one that often favors short-term economic gains over long-term preventative healthcare. The agency maintains that it “continues to consider regulatory initiatives related to sunlamp products,” but this feels like a deferral, not a commitment.
Original reporting: NBC News.
What’s particularly troubling is the existing disparity in regulations across the country. Currently, dozens of states – including California, Illinois, and Minnesota – already prohibit minors from using tanning beds, while others allow it with parental consent. The FDA’s withdrawal effectively leaves those states with protections intact, but creates a loophole for young people in states with laxer rules. Dr. Susan Taylor, president of the American Academy of Dermatology, rightly points out that relying on the industry to self-regulate is insufficient. “A warning might allow people to stop and think…but if you have a law that says those who are under 18 are not allowed to use these, that is enforceable,” she stated. The current “black-box” label – a warning against use by those under 18 – is rendered largely ineffective without a federal rule backing it up.
The debate also highlights a concerning lack of understanding among younger generations regarding the risks of tanning. A 2025 survey by the American Academy of Dermatology revealed that nearly 60% of adult Gen Zers believe common tanning myths, such as the idea that a “base tan” protects against sunburn. This misinformation, coupled with the allure of achieving a certain aesthetic, creates a dangerous vulnerability. Dr. Kendra Bergstrom of UW Medicine in Seattle emphasizes the carcinogenic nature of UV radiation, placing it in the same category as tobacco and asbestos. She also points out the difficulty consumers face in understanding the specific types of UV radiation emitted by tanning beds – UVA versus UVB – and their differing effects on the skin. While acknowledging the body’s need for some UV exposure for vitamin D production, she stresses that the risks far outweigh the benefits, particularly for young, developing skin.
The FDA’s decision isn’t simply a rollback of regulation; it’s a missed opportunity to standardize and strengthen protections against a known carcinogen. The agency’s stated concern for “compliance burdens on small businesses” feels particularly weak given the potential human cost. Moreover, the suggestion that awareness and prevention efforts are beginning to slow melanoma rates among younger people – a trend Dr. Bergstrom cautiously notes – is fragile and could easily be reversed without consistent, enforceable regulations. The question now isn’t whether the FDA will revisit this issue, but when, and whether they will prioritize public health over industry lobbying and the illusion of individual choice when it comes to a demonstrably dangerous practice. Will we see a rise in melanoma cases in states without restrictions, and will that data finally compel a more decisive federal response?
